Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453078 | 0.82 | KMT2A (0.80) | L3MBTL1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL5463030 | 0.81 | L3MBTL1 (0.56) | L3MBTL1MAPTTP53POLBKMT2A | |
| SCHEMBL5454130 | 0.81 | L3MBTL1 (0.66) | L3MBTL1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL3751801 | 0.78 | APEX1 (0.71) | L3MBTL1MAPTTP53LMNAPOLB | |
| SCHEMBL5460132 | 0.75 | L3MBTL1 (0.62) | L3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL5460249 | 0.75 | KMT2A (0.65) | L3MBTL1POLBKMT2AMEN1TSHR | |
| SCHEMBL5459233 | 0.74 | POLB (0.59) | L3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL13151131 | 0.73 | KMT2A (0.68) | L3MBTL1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL18902248 | 0.72 | KCNH2 (0.76) | MAPTLMNAPOLBKMT2AMEN1 | |
| SCHEMBL5454292 | 0.72 | KMT2A (0.76) | L3MBTL1MAPTLMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | L3MBTL1 2796/4885MAPT 21/4885TP53 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.